<DOC>
	<DOCNO>NCT00796445</DOCNO>
	<brief_summary>The purpose clinical trial evaluate benefit immunotherapeutic product GSK 2132231A prevent disease relapse give melanoma patient , surgical removal tumor . This Protocol Posting update follow Amendments 1 Protocol , March 2010 . The impacted section outcome measure entry criterion .</brief_summary>
	<brief_title>A Phase III Study Test Benefit New Kind Anti-cancer Treatment Patients With Melanoma , After Surgical Removal Their Tumor</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Written inform consent sign . Male female patient histologically proven stage IIIB IIIC cutaneous melanoma present macroscopic lymph node involvement suitable surgery . The patient must surgically render free disease randomization . Patient â‰¥ 18 year old time signing informed consent form . The patient 's lymph node tumor show expression MAGEA3 gene . The patient fully recover surgery . ECOG performance status 0 1 time randomization . The patient must adequate organ function assess standard laboratory criterion . If patient female , must nonchildbearing potential , practice adequate contraception . In opinion investigator , patient comply requirement protocol . The patient suffers mucosal ocular melanoma . The patient history intransit metastases The patient treat schedule treated adjuvant anticancer therapy surgery qualifies patient inclusion present trial . The patient require concomitant chronic treatment systemic corticosteroid immunosuppressive agent . Use investigational nonregistered product ( drug vaccine ) study treatment . The patient history autoimmune disease . The patient family history congenital hereditary immunodeficiency . The patient know positive Human Immunodeficiency Virus ( HIV ) another confirm suspect immunosuppressive immunodeficient condition . History allergic disease reaction likely exacerbate component treatment . The patient psychiatric addictive disorder may compromise his/her ability give inform consent comply trial procedure . The patient concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk . The patient previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer carcinoma situ cervix effectively treat malignancy remission 5 year highly likely cure . The patient uncontrolled bleed disorder . For female patient : patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>DERMA</keyword>
	<keyword>Tumor antigen</keyword>
	<keyword>Immunotherapeutic</keyword>
	<keyword>Adjuvant cancer therapy</keyword>
	<keyword>Melanoma</keyword>
	<keyword>ASCI</keyword>
</DOC>